Pan-European consortium collaborates on adenoviral vector Covid-19 vaccine

Allie Nawrat 23 April 2020 (Last Updated April 23rd, 2020 09:35)

Three companies across Europe, Italian ReiThera, German Leukocare and Belgian Univercells, have created a pan-European consortium to leverage their individual vaccine capabilities in the development and manufacturing of a novel adenoviral vector-based Covid-19 vaccine.

The vaccine candidate will target the spike protein of SARS-CoV-2, the virus causing Covid-19. ReiThera hopes to start clinical trials of the vaccine in Italy in the summer of 2020. While it is in development, the consortium will start large scale manufacturing and stockpiling of the vaccine, thereby allowing six million doses to be available by early 2021.

ReiThera chief technology officer Stefano Colloca said: “Covid-19 has transformed our society on a global scale, and has had a devastating effect, particularly in Italy. We are very eager to answer the calls from our industry and society to join the global effort against this rapidly spreading virus.

"We look forward to working with our partners, whose complementary expertise and capabilities will help this new consortium respond as quickly as possible to this global health emergency.”